New Lundbeck Foundation investment is first taste of changed strategy

The Danish foundation was part of the consortium, which also included Kirk Kapital and ATP, that acquired Ferrosan Medical Devices last week, bringing the fund one step closer to realizing its goal of having invested in a handful of healthcare companies by 2030.

Arne Due-Hansen, head of strategic investments at the Lundbeck Foundation | Photo: Lundbeckfonden / PR

It took almost two years before the Lundbeck Foundation dipped its toes in the investment waters under a new strategy, after a strategical shift was announced by CEO Lene Skole back in December 2020.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs